Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.34 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017774 | 0.91 | EGFR (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5041026 | 0.89 | MEN1 (0.37) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5042853 | 0.87 | KMT2A (0.33) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL6018087 | 0.87 | EGFR (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5036815 | 0.86 | ENPP1 (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5035960 | 0.85 | ENPP3 (0.39) | MAPTHTTENPP1ENPP2ENPP3 | |
| SCHEMBL5035909 | 0.85 | L3MBTL1 (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5041060 | 0.85 | ACE2 (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5042900 | 0.83 | MET (0.40) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL5033719 | 0.83 | MAPT (0.35) | MEN1KMT2AMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1298125-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | Aventis Pharma S.A. (FR) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | MEN1 3925/4885KMT2A 2114/4885MAPT 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.